ImmunoCAP(R) Used in Largest Cross-sectional Allergy Study Ever

By Phadia, PRNE
Thursday, May 26, 2011

UPPSALA, Sweden, May 27, 2011 -

Phadia, the worldwide leader of in vitro allergy diagnostics, is pleased
to contribute to the largest cross-sectional allergy study ever conducted
through the use of its ImmunoCAP(R) Specific IgE blood test, the market
leading in vitro allergy diagnostic test.

(Logo: Logo: )

The landmark study by Quest Diagnostics, the world's leading provider of
diagnostic testing, information, and services, includes test results from
over 2 million patients. The Health Trends Report(TM) confirms the "allergy
march" in which early childhood food allergies heighten the risk for
development of additional and more severe allergy-related conditions,
including asthma, later in life. In addition, the report shows that patients
with asthma are 20% more likely to have an allergic component to their
condition. This confirms that allergy testing and exposure reduction to a
patient's specific allergic triggers are critically important steps to take
for patients with asthma.

The study found that about half of patients tested (5 in 9) did not show
sensitization to at least one of 11 common allergens evaluated. While the
investigators hypothesize that some of these patients had an allergy to an
allergen not evaluated in the study, they also theorize that a large number
may have presented to their physician with allergy-like symptoms caused by a
non-allergy medical condition. The importance of identifying and ruling out
an allergy is important in order to improve quality of life for many

David Esposito, President and General Manager of Phadia US, says, "We
commend Quest Diagnostics on their leadership role in spotlighting the impact
of allergies in our nation. This data enables us to work together to support
health care reform initiatives that call for better patient care at reduced
costs. With full knowledge of their allergies and armed with an allergy or
asthma action plan, patients can reduce unscheduled doctors' office and
emergency room visits, lessen the need for medications including costly
inhaled corticosteroid/long-acting beta agonist combination medications, and
minimize sick days that cause missed school or work. Our hope is that this
data is used by payers and policy makers to support and embrace the NIH
Guidelines that recommend allergy testing for all patients with persistent

The study was based on 14 million de-identified test results. Each test
result identified sensitization to one or more of 11 common allergens: five
foods (egg white, milk, peanut, soybean and wheat), common ragweed, mold and
two types of house dust mites as well as cats and dogs.

Phadia will utilize data from the Quest Health Trends Report to expand
and extend the use of the ImmunoCAP Specific IgE blood test to support a
guidelines-based approach to diagnosing and managing allergic diseases.
Phadia and Quest Diagnostics have partnered to improve the diagnosis and
assessment of allergic disease for over two decades.

The full Allergies Across America Health Trends Report by Quest
Diagnostics was recently released. For more information please visit:

About Phadia

Phadia AB is a global leader in allergy, asthma and autoimmunity
diagnostics. Phadia develops, manufactures and markets complete blood test
systems to manage and support clinical diagnosis. Phadia has marketing
companies in more than 20 countries and distributors in more than 60

    Media Contact:
    Ulf Bladin
    VP Marketing, Corporate Communication, Scientific Affairs
    Tel. +46-18-16-50-00





will not be displayed